Dutch diagnostics firm Qiagen has recorded a solid second quarter, helped by particularly good growth in sales of its HPV screening tests. Revenue for the period was $262.7m, up 9% on the same quarter last year. Excluding the negative impact of foreign currency rates, revenue growth ...
Please Login to read the full article.
